Last reviewed · How we verify
NCT06696794
Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients
Phase 3 trial testing Mitomycin C (MMC) in Non-Muscle-Invasive Bladder Cancer (NMIBC) in 180 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | Shaogang Wang |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 17 February 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 June 2031 |
| Sites | 3 locations across China |
Drugs / interventions tested
- Mitomycin C (MMC) — full drug profile →
- Normal Saline (Placebo) — full drug profile →
Conditions studied
- Non-Muscle-Invasive Bladder Cancer (NMIBC) — all drugs for Non-Muscle-Invasive Bladder Cancer (NMIBC) →
Sponsor
Shaogang Wang
Who can join
Adults 18 to 75, any sex, with Non-Muscle-Invasive Bladder Cancer (NMIBC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn if neoadjuvant intravesical instillation of mitomycin C combined with en-bloc surgery works to treat high-risk non-muscle-invasive bladder cancer (NMIBC) patients. It will also learn about the safety of neoadjuvant intravesical instillation of mitomycin C. The main questions it aims to answer are: Does neoadjuvant intravesical instillation of mitomycin C heighten the 1-year recurrence-free survival (RFS) rate for high-risk non-muscle-invasive bladder cancer (NMIBC) patients? What medical problems do participants have when taking neoadjuvant intravesical instillation of mitomycin C? Researchers will compare neoadjuvant intravesical instillation of mitomycin C to a placebo (normal saline) to see if neoadjuvant intravesical instillation of mitomycin C works to treat high-risk NMIBC. Participants will: Take neoadjuvant intravesical instillation of mitomycin C or a placebo twice，1 day and 4 hours before en-bloc surgery Visit the clinic once every 8 weeks for checkups and tests Keep track of the recurrence and progression of the tumor.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06696794
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Mitomycin C (MMC)
Trials testing the same drug.
- NCT04241185 — Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-in · Phase 3 · active not recruiting
Other recruiting trials for Non-Muscle-Invasive Bladder Cancer (NMIBC)
Currently open trials in the same condition.
- NCT07339761 — Supporting Sexual Health in Bladder Cancer Patients: A Sequential Mixed-Methods Intervention Study · NA · recruiting
- NCT06351904 — A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin ( · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06696794 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shaogang Wang
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06696794.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing